Skip to main content
    C

    CONMED Corporation (CNMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $49.35
    -1.24 (-2.45%)

    Market Cap: $1.51B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CONMED Corporation (CNMD) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    CONMED (CNMD) trades at 10.4x trailing earnings and 1.1x sales. Its P/E of 10.4x is below its 5-year median of 20.5x. Its forward P/E is 27.2x. The median P/E across 7 similar companies is 29.1x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 61.8% lower over the next year. Its free cash flow yield is 9.0%.

    MultipleValue
    P/E (trailing)10.4x
    Forward P/E27.2x
    Price to sales1.1x
    Price to book1.4x
    EV/EBITDA10.3x
    Price to FCF11.1x
    EV/FCF16.9x
    PEG1.8
    FCF yield9.0%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 66.7% below 31.2x, its P/S is 52.2% below 2.3x and its P/B is 54.8% below 3.1x.

    MultipleCurrent5-year median10-year median
    P/E10.4x20.5x31.2x
    P/S1.1x1.8x2.3x
    P/B1.4x2.7x3.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 8.8x in 2025 to 51.9x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$40.608.8x0.9x1.2x
    2024$68.4416.5x1.6x2.2x
    2023$109.5131.7x2.7x4.1x
    2022$88.6433.4x2.6x3.7x
    2021$141.7644.2x4.2x5.9x
    2020$112.0051.9x3.8x4.7x
    2019$111.8342.2x3.4x4.8x
    2018$64.2029.4x2.1x2.8x
    2017$50.9726.8x1.8x2.3x
    2016$44.1727.4x1.6x2.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CNMD

    What is CNMD's forward P/E ratio?

    CONMED has a forward P/E ratio of 27.2x.

    Is CNMD stock overvalued?

    GNG's valuation label for CNMD is Fairly valued. Its P/E of 10.4x compares with a median of 29.1x across 7 similar companies.

    What is CNMD's price to sales ratio?

    CONMED has a price to sales ratio of 1.1x.

    What is CONMED's average P/E ratio over 5 years?

    CONMED's median P/E over the last 5 years is 20.5x, from 60 month-end values through Oct 2026.

    What is CNMD's PEG ratio?

    CONMED has a PEG ratio of 1.8.